Monday, Apr 8, 1996

Appeals Court Upholds Preliminary Injunction Prohibiting Sales of Biotechnology General's Growth Hormone Product

South San Francisco, Calif. -- April 8, 1996 --

Genentech, Inc. (NYSE: GNE) today announced that a preliminary injunction preventing Biotechnology General Corporation and its affiliates (BTG) from marketing their human growth hormone product in the United States has been upheld by the Court of Appeals for the Federal Circuit.

The preliminary injunction states that it will be in effect pending final determination of the action. Genentech claims that BTG infringes Genentech's U.S. patents that relate to the manufacture of human growth hormone.

On June 28, 1995 a District Court in New York granted a preliminary injunction preventing BTG from marketing their human growth hormone product in the United States. Subsequent to that decision, BTG appealed the decision to the Court of Appeals for the Federal Circuit. Today, that appellate court upheld the preliminary injunction against BTG.

"We are very pleased that the Court of Appeals for the Federal Circuit has upheld the preliminary injunction against BTG," said Stephen Raines, Genentech's vice president for Intellectual Property. "Genentech remains convinced that the sale of BTG's product will be permanently prohibited at the end of the full hearing before the District Court, which will be held at a later date."

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. The company has headquarters in South San Francisco and is traded on the New York and Pacific stock exchanges under the symbol GNE.

# # #